CytoDyn Inc.
CYDY
$0.25
-$0.01-2.40%
OTC PK
| 11/30/2025 | 08/31/2025 | 05/31/2025 | 02/28/2025 | 11/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 1.80M | 1.71M | 1.85M | 1.51M | 2.30M |
| Depreciation & Amortization | -- | -- | -14.00K | 5.00K | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 5.10M | 4.95M | 5.07M | 4.00M | 3.71M |
| Operating Income | -5.10M | -4.95M | -5.07M | -4.00M | -3.71M |
| Income Before Tax | -22.61M | -5.54M | -5.96M | -4.76M | -4.77M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -22.61M | -5.54M | -5.96M | -4.76M | -4.77M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -22.61M | -5.54M | -5.96M | -4.76M | -4.77M |
| EBIT | -5.10M | -4.95M | -5.07M | -4.00M | -3.71M |
| EBITDA | -5.10M | -4.94M | -5.06M | -4.00M | -3.70M |
| EPS Basic | -0.02 | 0.00 | -0.01 | 0.00 | 0.00 |
| Normalized Basic EPS | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS Diluted | -0.02 | 0.00 | -0.01 | 0.00 | 0.00 |
| Normalized Diluted EPS | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Average Basic Shares Outstanding | 1.26B | 1.25B | 1.24B | 1.23B | 1.22B |
| Average Diluted Shares Outstanding | 1.26B | 1.25B | 1.24B | 1.23B | 1.22B |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |